Scientists Move Closer to Solving Arthritic Condition in Teens

by Colleen Fleiss on  August 25, 2018 at 10:50 PM Research News
RSS Email Print This Page Comment bookmark
Font : A-A+

A new Michigan State University study has found that Malfunctioning Endoplasmic Reticulum Aminopeptidase 1, or ERAP1 gene associated with a common arthritic disease that often starts in teenagers is now directly linked to the loss of vital immune cells that may prevent it. The findings of the study are published in Scientific Reports.
Scientists Move Closer to Solving Arthritic Condition in Teens
Scientists Move Closer to Solving Arthritic Condition in Teens

Also known as AS, the autoimmune disorder affects millions worldwide, mostly developing in the hips and spines of those as young as 17 years old and lasting throughout life.

But how changes in the gene result in the condition has remained somewhat of a mystery.

"We've demonstrated in mice that loss of proper ERAP1 activity correlates with loss of certain immune cells called Tr1s, which we know are directly responsible for controlling excessive immune responses that can attack healthy tissue and cells," said Andrea Amalfitano, an Osteopathic Heritage Foundation professor who led the study with Yuliya Pepelyayeva, a doctoral student in MSU's microbiology and molecular genetics program. "Our finding allows us to zero in on the role the gene and Tr1 cells have in AS."

In the case of autoimmune disorders, the immune system can no longer tell the difference between good, healthy cells and bad, diseased cells. This often results in an extreme immune reaction where the body starts to overcompensate and attack itself.

Because of this response, patients with AS experience bony fusions between the joints of the pelvis and spine, which cause chronic pain and disability. They also can suffer from other health issues including problems with the gut and intestine.

"We know that Tr1 cells are implicated in digestive issues such as inflammatory bowel disease, and it's possible that the reduction of these cells is responsible for the increased inflammatory responses we saw in mice and is associated with ankylosing spondylitis as well," Pepelyayeva said.

With this new insight, both researchers are now testing cells in human blood samples and will move to human trials in the coming years to see if their findings are consistent.

"There's more work to be done, but a new immunotherapy treatment where more Tr1 cells are infused back into the patient, ultimately correcting the deficiency, could be a possibility," Pepelyayeva said.

This new treatment, she added, would potentially help regulate the way the immune system responds and might correct any inflammation in the spine and spinal fusions.

Amalfitano also indicated that scientists can now focus on this potential relationship between gene and immune cell and look at it as a possible cause of not just AS, but several other autoimmune diseases, too.

The study was funded in part by the National Institutes of Health.

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions
Advertisement

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive